Tuesday, November 29, 2016

Novo Nordisk says Tresiba insulin achieves target in DEVOTE study

COPENHAGEN, Nov 29 (Reuters) - Novo Nordisk's

long-acting insulin blockbuster Tresiba has a safe

cardiovascular profile in patients with type 2 diabetes, results

released by the company on Tuesday showed.

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)